Leerink Partnrs Forecasts Stronger Earnings for 10x Genomics

10x Genomics (NASDAQ:TXG) – Equities research analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for 10x Genomics in a research note issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of ($0.28). The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for 10x Genomics’ Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.90) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.91) EPS and FY2027 earnings at ($0.57) EPS.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS.

Other equities analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the company a “hold” rating in a report on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a report on Tuesday. Piper Sandler started coverage on shares of 10x Genomics in a report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 target price on the stock. Bank of America boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, June 26th. Finally, Morgan Stanley lowered their target price on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $13.65.

10x Genomics Price Performance

Shares of NASDAQ:TXG opened at $12.38 on Thursday. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $18.21. The company has a market capitalization of $1.54 billion, a P/E ratio of -17.69 and a beta of 2.05. The firm’s 50 day simple moving average is $12.88 and its two-hundred day simple moving average is $11.13.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Allworth Financial LP grew its holdings in shares of 10x Genomics by 150.4% in the second quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after purchasing an additional 1,364 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after purchasing an additional 1,614 shares during the last quarter. Signaturefd LLC grew its holdings in shares of 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after purchasing an additional 2,409 shares during the last quarter. Whittier Trust Co. bought a new position in shares of 10x Genomics in the first quarter worth about $41,000. Finally, True Wealth Design LLC grew its holdings in shares of 10x Genomics by 1,552.5% in the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after purchasing an additional 3,369 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Serge Saxonov sold 9,348 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares in the company, valued at $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,149 shares of company stock valued at $539,865 over the last 90 days. 9.39% of the stock is owned by corporate insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.